In July 2008, in France, guidelines for antibiotic prescriptions for urinary tract infections (UTIs) were amended.

OBJECTIVES:Controversy exists regarding the benefit of open anti-reflux surgery (OS) in reducing the incidence of urinary tract infection (UTI).

BACKGROUND:Infection is a serious adverse effect of prostate biopsy (P-Bx), and recent reports suggest an increasing incidence.

INTRODUCTION:Urinary tract infection (UTI) is a common disease in the community, and a matter of concern due to the increasing resistance of microorganisms to first line antibiotics and the emergence of multiresistant strains producing extended spectrum beta lactamases (ESBL) in the community.

Urinary tract infections (UTI) in pregnant women are a relatively frequent occurrence and the spectrum of these infections ranges from lower urinary tract disease (asymptomatic bacteriuria, acute cystitis) to upper urinary tract disease (acute pyelonephritis).

BACKGROUND:Extended-spectrum beta-lactamase (ESBL) resistance is a growing concern in and outside hospitals.

BACKGROUND:Optimal treatment regimens for infections caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae are not well-defined.

Background:Little is known about the role of asymptomatic bacteriuria (AB) treatment in young women affected by recurrent urinary tract infection (UTI).

Voiding cystourethrography (VCUG) is a commonly performed diagnostic procedure for the evaluation of vesicoureteral reflux with urinary tract infection or congenital renal diseases in children.

BACKGROUND:Knowledge of local antimicrobial resistance patterns is essential for evidence-based empirical antibiotic prescribing, and a cutoff point of 20 % has been suggested as the level of resistance at which an agent should no longer be used empirically.

BACKGROUND:Extended-spectrum β-lactamases (ESBLs) have emerged as an important mechanism of β-lactam resistance among community uropathogens.

INTRODUCTION: Understanding the uropathogens causing urinary tract infection (UTI) and their susceptibility to antibiotics is important to physicians who are choosing antibiotic therapy.

INTRODUCTION: The purpose of the study was to compare the accuracy of plain radiography, 2-dimensional (2D), and 3-dimensional (3D) transrectal ultrasound (TRUS) in diagnosing the causes of acute dysuria, as confirmed by urethroscopy or laboratory findings.

Urinary tract infection (UTI) is among the most common infectious diseases of humans and is the most common nosocomial infection in the developed world.

OBJECTIVE: To determine the relation between postvoid residual (PVR) and the occurrence of urinary tract infection (UTI) in stroke patients.

Urinary tract infections (UTIs) are among the most frequent community-acquired infections worldwide. Escherichia coli is the most common UTI pathogen although underlying host factors such as patients' age and gender may influence prevalence of causative agents.

Urinary tract infection (UTI) is a potentially life-threatening infectious disease.

The discovery of antimicrobials as β-lactam antibiotics or aminoglycosides revolutionized the treatment of infectious diseases.

OBJECTIVE: The National Institute of Clinical Excellence (NICE) published guidelines in 2010 recommending the use of cystoscopy to investigate profound lower urinary tract symptoms (pLUTS), recurrent urinary tract infection (rUTI) and pain in men.

BOTHELL, WA USA (Press Release) - July 30, 2012 /PRNewswire via COMTEX/ -- Verathon® Inc. announced today new free, online CAUTI prevention educational materials for healthcare providers at http://verathon.com/products/bladderscan/cauti-zero.

These comprehensive materials include an easy-to-remember CAUTI bundle in poster and animated form, instructional videos with Diane Newman, a renowned expert on urinary issues, an interactive timeline with facts and figures on CAUTI, and additional downloadable educational materials for use by those working to lower and eliminate catheter-associated UTIs in their facilities.

Lowering the high cost of CAUTI.

The Centers for Disease Control and Prevention (CDC) estimates that the direct medical costs of treating healthcare-associated infections (HAIs) in the United States is as high as $45 billion per year.¹

Catheter-associated UTIs, the most common HAI, represent 36% of total HAIs. Because CAUTIs have been a prevalent patient safety issue, the Centers for Medicare and Medicaid Services (CMS) in October 2008 issued a new regulation to end reimbursement for the additional costs incurred from preventable CAUTI.²

A national hospital survey, administered by the University of Michigan, examined prevention practices in use between 2005 and 2009. While CAUTI prevention practices remain inadequate, the only practice used by 50% or more of the hospitals was portable bladder volume ultrasound.³

Helping nurses meet the CAUTI challenge.

As the manufacturer of BladderScan® portable bladder volume ultrasound instruments, Verathon is proud to play a key role in supporting CAUTI prevention education that can help nurses and infection prevention staff eliminate unnecessary urinary (Foley) catheterization and reduce costs.

"The Joint Commission has made CAUTIs a 2012 National Patient Safety Goal," states CAUTI expert Diane K. Newman, DNP FAAN BCB-PMD. "Increasing awareness of best practices for minimizing catheterization and ensuring early Foley catheter removal clearly helps promote safe patient care, while reducing costs from unnecessary catheter-associated UTIs."

To help nurses meet this National Patient Safety Goal, Verathon is providing the following free educational tools online to help raise awareness about CAUTI prevention practices:

White Paper: This updated version of "Removing Indwelling Catheters in Acute Care: A Step-By-Step Clinical Pathway for Nurses" by Diane K. Newman provides the most current evidence-based clinical information on managing Foley catheters. Available at UroToday and http://verathon.com/products/bladderscan/cauti-zero.

CAUTI Bundle Poster: Designed for staff lounges and nursing stations, this eye-catching poster displays a CAUTI bundle checklist in five memorable steps. Downloadable PDF available at UroToday and http://verathon.com/products/bladderscan/cauti-zero .

CAUTI Bundle Checklist (animated): This animated version of the checklist is perfect for presentations to staff on CAUTI elimination best practices. Available at http://verathon.com/products/bladderscan/cauti-zero .

CAUTI Interactive Timeline: This compelling "CAUTI Chronology" offers a decade of fast facts in the fight against CAUTI. Downloadable PDF available at UroToday and http://verathon.com/products/bladderscan/cauti-zero .

Demonstration Videos: Learn how to measure bladder volume with the BladderScan portable ultrasound device in these three patient demonstration videos presented by Diane K. Newman. Now showing on YouTube, UroToday and http://verathon.com/products/bladderscan/cauti-zero .

Acute Care Manual: "Managing Urinary Retention in the Acute Care Setting" is a comprehensive guide to safe patient care through the application of noninvasive bladder management. Available at http://verathon.com/products/bladderscan/cauti-zero .

On the front line of CAUTI prevention.

Verathon and UroToday, the leading global urological disease-focused online resource, launched the CAUTI Center in December 2009 to provide access to the latest commentary from CAUTI expert Diane Newman, as well as recent publications and experiences from those in the CAUTI treatment community. Today, that center, now known as The CAUTI Challenge, has become a definitive source of CAUTI prevention information for practitioners.

"UroToday is extremely proud of The CAUTI Challenge effort," says Gina Carithers, CEO of UroToday and Publisher of UroToday International Journal. "UroToday, Diane Newman and the team at BladderScan, are steadfastly committed to providing the best educational tools to assist healthcare professionals in reducing, and ultimately eliminating, dangerous and costly catheter-associated urinary tract infections."

 About Verathon Inc.

Verathon designs and manufactures reliable, state-of-the-art medical devices and services that offer a meaningful improvement in patient care to the healthcare community. The company's noninvasive BladderScan® instrument is a standard of care for portable bladder volume measurement. The brand is found in over 60 countries in Acute Care, Urology and Primary Care practices, as well as Extended Care facilities. With the January 2006 acquisition of Saturn Biomedical Systems in Vancouver, Canada, Verathon entered Anesthesiology, Critical Care and Emergency markets with the GlideScope® video laryngoscope brand. Verathon is headquartered in Bothell, Washington and operates as a subsidiary of Roper Industries. For more information, please visit verathon.com.

About Roper Industries

Roper Industries is a market-driven, diversified growth company and is a constituent of the S&P 500, Fortune 1000, and the Russell 1000 indices. Roper provides engineered products and solutions for global niche markets, including water, energy, transportation, medical, education, and SaaS-based information networks. Additional information about Roper Industries is available on the Company's website at roperind.com.

Verathon Media Contacts:

Lorraine Silva, Director - Marketing Operations, Verathon Medical, 425.867.1348 (Ext. 5604).
Alternate Contact: Jane Mueller, VP of Marketing, 425.867.1348 (Ext. 5600).

References:

1. Centers for Disease Control and Prevention. (2009) The direct medical costs of healthcare associated infections in U.S. hospital and the benefits of prevention. Available at: http://cautichallenge.com/images/stories/files/Scott_CostPaper-20120127171513.pdf . Accessed on February 14, 2012.
2. Centers for Medicare & Medicaid Services Web site. Available at: http://www.cms.gov . Accessed on October 20, 2011.
3. Krein SL, Kowalski CP, Hofer TP, et al. Preventing hospital-acquired infections: a national survey of practices reported by U.S. hospitals in 2005 and 2009. J Gen Intern Med 2011. http://www.ncbi.nlm.nih.gov/pubmed/22143455 Accessed January 5, 2012.

Verathon, Inc.

All of the resources detailed in this release are also available at www.cautichallenge.com.

[ PRESS RELEASE ]